jlk;u vkSj moZjd ea=kky;

¼vkS"k/k foHkkx½

¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3762¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k%

rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

ukbVªl vkWDlkbM bUgsys'ku

D;wfcd ehVj

206.18

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

jftLVªh laö Mhö ,yö&33004@99

REGD. NO. D. L.-33004/99

vlk/kj.k

EXTRAORDINARY

Hkkx II—[k.M 3—mi&[k.M (ii)

PART II—Section 3—Sub-section (ii)

izkf/dkj ls izdkf'kr

PUBLISHED BY AUTHORITY

la- 2872]

ubZ fnYyh] 'kqØokj] fnlEcj 20] 2013@vxzgk;.k 29] 1935

No. 2872]

NEW DELHI, FRIDAY, DECEMBER 20, 2013/AGRAHAYANA 29, 1935

5358 GI/2013

(1)

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

MINISTRY OF CHEMICALS AND FERTILIZERS

(Department of Pharmaceuticals)

(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)

ORDER

New Delhi, the 20th December, 2013

S.O. 3762(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E), dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereinbelow as ceiling prices exclusive of local tax applicable, if any in respect

of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Nitrous Oxide Inhalation

Cubic Meter

206.18

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraphs 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the abovesaid date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3763¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh

Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

vkWDlht+u bUgsys'ku

D;wfcd ehVj

15.81

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3763(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereinbelow as ceiling prices exclusive of local tax applicable, if any in respect

of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Oxygen Inhalation

Cubic Meter

15.81

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the abovesaid date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3764¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k%

rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

gsikfju lksfM;e bUtsD'ku

1000 vkbZ;w @fefy

1 fefy

17.50

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3764(E).—In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table herein below as ceiling prices exclusive of local tax applicable, if any in

respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the

strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Heparin Sodium Injection

1000 IU/ml

1ml

17.50

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentione scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3765¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k%

rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

lDlhuk;y dksfyu DyksjkbM bUtsD'ku

50 fexzk-@fefy

1 fefy

6.04

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3765(E).—In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any in respect

of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Schedule Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Succinyl Choline Chloride Injection

50mg /ml

1ml

6.04

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the abovesaid date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3766¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 6, 11 vkSj 14 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh

Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

bFkk;y ,YdksgWy 70% lksY;w'ku

1 fefy-

0.49

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks] ds

vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3766(E).—In exercise of the powers, conferred by paragraphs 4, 6, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with No. S.O. 1394(E), dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table herein below as ceiling prices exclusive of local tax applicable, if any in

respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the

strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Ethyl Alcohol 70% Solution

—

1 ml

0.49

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraphs 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3767¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 6, 11 vkSj 14 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh

Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

tSfUV;ku okW;ysV iSUV

1 fefy-

0.06

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3767(E).—In exercise of the powers, conferred by paragraph 4, 6, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with No. S.O. 1394(E), dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereinbelow as ceiling prices exclusive of local tax applicable, if any in respect

of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Gentian Violet Paint

1 ml

0.06

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraphs 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3768¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 6, 11 vkSj 14 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh

Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

gkbMªkst+u isjksDlkbM lksY;w'ku

1 fefy-

0.05

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3768(E).—In exercise of the powers, conferred by paragraphs 4, 6, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table herein below as ceiling price, exclusive of local tax applicable, if any in respect

of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Hydrogen Peroxide Solution

1 ml

0.05

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of Scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3769¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ds vkns'k la-

dk-vk- 1907¼v½] fnukad 28 twu] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks

mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds

LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre

dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

feFkk;y ,jxksesVjkbu bUtsD'ku

0.2 fexzk-@fefy

1 fefy

13.41

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3769(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1907(E), dated the 28th June, 2013, hereby fixes the prices

as specified in column (5) of the Table herein below as ceiling prices exclusive of local tax applicable, if any in respect of

the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Methyl Ergometrine Injection

0.2 mg/ml

1 ml

13.41

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraphs 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3770¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ds vkns'k la-

dk-vk- 2058(v), fnukad 5 tqykbZ] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks

mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds

LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre

dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

esVksizksyksy xksfy;ka

25 fexzk-

1 xksyh

3.38

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr vf/kdre dher ,l&esVksizksyksy ;qDr fofufeZfr;ksa ij ykxw ugha gksxhA

¼p½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼N½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼t½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼>½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

ORDER

New Delhi, the 20th December, 2013

S.O. 3770(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 2058(E), dated the 5th July, 2013, hereby fixes the prices as

specified in column (5) of the Table hereinbelow as ceiling prices exclusive of local tax applicable, if any in respect of the

Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Metoprolol Tablets

25 mg

1 Tablet

3.38

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraphs 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The above ceiling price may not be applicable to the formulations containing S-Metoprolol.

(g)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of Scheduled formulation in Form-IV of Scheduled-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(h)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(i)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3771¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ds vkns'k la-

dk-vk- 2059(v), fnukad 5 tqykbZ] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks

mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds

LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre

dher ds :i esa fu;r djrh gSA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

esVksizksyksy xksfy;ka

50 fexzk-

1 xksyh

5.01

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr vf/kdre dher ,l&esVksizksyksy ;qDr fofufeZfr;ksa ij ykxw ugha gksxhA

¼p½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼N½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼t½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼>½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3771(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 2059(E), dated the 5th July, 2013, hereby fixes the prices as

specified in column (5) of the Table herein below as ceiling prices exclusive of local tax applicable, if any in respect of the

Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Metoprolol Tablets

50 mg.

1 Tablet

5.01

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The above ceiling price may not be applicable to the formulations containing S-Metoprolol.

(g)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(h)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(i)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the abovesaid date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3772¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ds vkns'k la-

dk-vk- 1808(v), fnukad 21 twu] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr

lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk

¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher

ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

,EyksfMfiu xksfy;ka

2.5 fexzk-

1 xksyh

1.79

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr vf/kdre dher ,l&,EyksfMfiu ;qDr fofufeZfr;ksa ij ykxw ugha gksxhA

¼p½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼N½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼t½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼>½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3772(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in superession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1808(E), dated the 21st June, 2013, hereby fixes the prices

as specified in column (5) of the Table herein below as ceiling prices exclusive of local tax applicable, if any in respect of

the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Amlodipine Tablets

2.5 mg

1 Tablet

1.79

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The above ceiling price may not be applicable to the formulations containing S-Amlodipine.

(g)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(h)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(i)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3773¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ds vkns'k la-

dk-vk- 1809(v), fnukad 21 twu] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr

lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk

¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher

ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

,EyksfMfiu xksfy;ka

5 fexzk-

1 xksyh

2.83

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr vf/kdre dher ,l&,EyksfMfiu ;qDr fofufeZfr;ksa ij ykxw ugha gksxhA

¼p½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼N½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼t½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼>½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3773(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in superession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1809(E), dated the 21st June, 2013, hereby fixes the prices

as specified in column (5) of the Table hereinbelow as ceiling prices exclusive of local tax applicable, if any in respect of the

scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Amlodipine Tablets

5 mg

1 Tablet

2.83

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The above ceiling price may not be applicable to the formulations containing S-Amlodipine.

(g)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(h)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(i)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above Table

in this notification, the price order(s) if any, issued prior to the above said date of Notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3774¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 11 vkSj 14 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ds vkns'k la-

dk-vk- 2532(v), fnukad 21 vxLr] 2013 vkSj dk-vk- 3211(v), fnukad 21 vxLr] 2013 dks vf/kØe.k djrs gq,] uhps dh lkj.kh

ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk

vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] LFkkuh;

dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

vf/kdre dher

¼#-½

vkWjy iksfy;kek;ysfVl osfDlu ¼,y,½ lksY;w'ku

1 fefy

99.90

uksV %

¼d½

mi;qZDr lkj.kh ds LraHk ¼5½ esa vf/kdre [kqnjk dher gksus ds Åij mYysf[kr vuqlwfpr fofufeZfr;ksa ds fuekZrkvksa dks

Mhihlhvks] 2013 ds iSjkxzkQ 13 ¼1½ vkSj iSjk 24 ds rgr vf/kdre dher ls vf/kd LFkkuh; dj] tgka dgha Hkh ykxw gks]

ds vuqlkj vukf/kd vf/kd [kqnjk dher dks la'kksf/kr djsxkA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼?k½

lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa

fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds

iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA

¼³½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds

vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼p½

mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k

dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj

vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II

ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d

oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus

ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa ds iSdksa dh vf/kdre

dher fu;r gksus ds ifj.kke Lo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3774(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, and in superession of the Order of the Government of India in the Ministry of Chemicals and

Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 2532(E), dated the 21st August, 2013 and S.O. 3211(E),

dated 21st October, 2013, hereby fixes the prices as specified in column (5) of the Table herein below as ceiling prices

exclusive of local tax applicable, if any in respect of the scheduled formulations specified in the corresponding entry in

column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3)

and (4) thereof:

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Oral Poliomyelitis vaccine (LA) Solution

1 ml

99.90

Note :

(a)

The manufacturers of above mentioned scheduled formulations having maximum retail price higher than the ceiling

price specified in column (5) of the Table hereinabove, shall revise the MRP to an amount not exceeding the ceiling

price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO, 2013.

(b)

The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the

ceiling price mentioned in the column (5) of the above Table.

(c)

The ceiling price for a pack of the scheduled formulation shall be arrived at by the manufacturer in accordance with

the ceiling price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the Drugs

(Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the

DPCO, 2013.

(d)

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price

specified in column (5) in the above Table plus local taxes as applicable, if any, shall continue to maintain the existing

MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(e)

Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then such existing manufacturer shall apply for

prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of

production/import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer

intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of

discontinuation of the production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO,

2013 at least six months prior to the indented date of discontinuation.

(g)

The manufacturer not complying with the ceiling price and notes specified hereinabove in this notification, shall be

liable to deposit overcharged amount along with the interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h)

Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above table

in this notification, the price order(s) if any, issued prior to the above said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3775¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ ,yfEcd fyfeVsM

fu£[email protected] fofu£n"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bZdkbZ

[kqnjk ewY;

¼#-½

izR;sd vfyfir ck;ys;MZ xksfy;ksa esa

oksxfycksl$fxykbeijkbM$

oksxfycksl-0.2 fexzk-

1 xksyh

8.48

esVQksjfeu ,plh,y xksfy;ka

fxykbeijkbM-1 fexzk-

¼Xykblsu oh,e 1 xksfy;ka½

esVQksjfeu ,plh,y

¼lLVsUM fjfyt+ QkWeZ esa½-500 fexzk-

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3775(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s.

Alembic Ltd.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Ceiling Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each uncoated bilayer tablet contains

Voglibose+ Glimeperide+

Voglibose – 0.2mg

1 Tablet

8.48

Metformin HCL Tablets

Glimeperide-1mg

(Glisen VM1 tablet)

Metformin HCL (in sustained

release form)-500mg

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

Table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3776¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ ,yfEcd fyfeVsM

fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh

gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd vfyfir ck;ys;MZ xksfy;ksa esa

foxksfycksl$fxykbeijkbM$

foxksfycksl-0.2 fexzk-

1 xksyh

10.79

esVQksjfeu ,plh,y xksfy;ka

fxykbeijkbM-2 fexzk-

¼Xykblsu oh,e 2 xksfy;ka½

esVQksjfeu ,plh,y

¼lLVsUM fjfyt+ QkWeZ esa½-500 fexzk-

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼Ä½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkj dj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gaS] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3776(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with No. S.O. 1394(E), dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by

M/s. Alembic Ltd.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each uncoated bilayer tablet contains

Voglibose+ Glimeperide

Voglibose – 0.2 mg

1 Tablet

10.79

Metformin HCL Tablets

Glimeperide – 2 mg

(Glisen VM2 tablet)

Metformin HCL (in sustained

release form)-500 mg

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the Table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above Table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above Table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

Table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3777¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ fcY;w Økl ysc] fyfeVsM

fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh

gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir xksfy;ksa esa

vksyeslkjVu esMksDlksfey$

vksyeslkjVu esMksDlksfey chih-20 fexzk-

1 xksyh

7.10

gkbMªksDyksjfFk;kft+M xksfy;ka

gkbMªksDyksjfFk;kft+M-12.5 fexzk-

¼vksyesCyw - ,p 20 xksfy;ka½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3777(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price, exclusive of local taxes, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s. Blue

Cross Lab. Limited.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated tablet contains

Olmesartan Medoxomil +

Olmesartan Medoxomil BP– 20mg

1 Tablet

7.10

Hydrochlorthiazide Tablet

Hydrochlorthiazide-12.5mg

(Olmeblu – H 20 tablet)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3778¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ fcY;w ØkWl ysc- fyfeVsM

fu£[email protected] fofu£n"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir xksfy;ksa esa

vksyeslkjVu esMksDlksfey$

vksyeslkjVu esMksDlksfey chih-40 fexzk-

1 xksyh

11.52

gkbMªksDyksjfFk;kft+M xksfy;ka

gkbMªksDyksjfFk;kft+M-12.5 fexzk-

¼vksyesCyw-,p 40 xksfy;ka½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3778(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price, exclusive of local tax, if any in retail to each

of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified

respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s. Blue Cross Lab.

Limited.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated tablet contains

Olmesartan Medoxomil +

Olmesartan Medoxomil BP– 40 mg

1 Tablet

11.52

Hydrochlorthiazide Tablet

Hydrochlorthiazide-12.5 mg

(Olmeblu – H 40 tablet)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3779¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh

izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ fcY;w ØkWl ysc-

fyfeVsM fu£[email protected] fofu£n"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i

esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir xksfy;ksa esa

vksyeslkjVu esMksDlksfey$

vksyeslkjVu esMksDlksfey chih-20 fexzk-

1 xksyh

7.55

,EyksfMfiu cslk;ysV xksfy;ka

,EyksfMfiu cslk;ysV-5 fexzk-

¼vksyesCyw - ,,e xksfy;ka½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk,xkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk,axsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3779(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price, exclusive of local taxes, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s. Blue

Cross Lab. Limited.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated tablet contains

Olmesartan Medoxomil +

Olmesartan Medoxomil BP–20 mg

1 Tablet

7.55

Amlodipine Besylate Tablet

Amlodipine Besylate – 5 mg

(Olmeblu – AM tablet)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3780¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½] rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ IysufV;l QkekZL;wfVdy

fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r

djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd vfyfir ck;ys;MZ xksfy;ksa esa

VsYehlkjVu $

VsYehlkjVu 40 fexzk-

1 xksyh

7.47

gkbMªksDyksjfFk;kft+M xksfy;ka

gkbMªksDyksjfFk;kft+M-12.5 fexzk-

uksV %

¼d½

fofuZekZrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3780(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with No. S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

price as specified in column (5) of the Table hereto annexed as the retail price exclusive of local taxes, if any in retation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by

M/s. Plenteous Pharmaceuticals.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each uncoated bilayered tablet contains

Telmisartan +

Telmisartan –40 mg.

1 Tablet

7.47

Hydrochlorhiazide tablet

Hydrochlorothiazide –12.5 mg.

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production / import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3781¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh

izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ vtUrk QkekZ fyfeVsM

fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r

djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir ck;ys;MZ xksfy;ksa esa

VsYehlkjVu $

VsYehlkjVu 40 fexzk-

1 xksyh

9.62

esVksizksyksy VkjVªsV bZvkj xksfy;ka

esVksizksyksy lDlhusV-47.5 fexzk-

esVksizksyksy VkjVªsV -50 fexzk- ds cjkcj

¼,DlVsUMsM fjfyt+ QkWeZ esa½

uksV %

¼d½

fofuZekZrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3781(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with No. S.O. 1394(E), dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price, exclusive of local taxs, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by

M/s. Ajanta Pharma Limited.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated bilayered tablet contains

Telmisartan +

Telmisartan –40 mg

1 Tablet

9.62

Metoprolol Tartrate

Metoprolol succinate – 47.5 mg eq. to

ER Tablet

Metoprolol Tartrate– 50 mg

(as extended release form)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2(u) of DPCO, 2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production / import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3782¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ vtUrk QkekZ fyfeVsM

fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r

djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir ck;ys;MZ xksfy;ksa esa

VsYehlkjVu $

VsYehlkjVu 40 fexzk-

1 xksyh

8.10

esVksizksyksy VkjVªsV bZvkj xksfy;ka

esVksizksyksy lDlhusV-23.75 fexzk-

esVksizksyksy VkjVªsV -25 fexzk- ds cjkcj

¼,DlVsUMsM fjfyt+ QkWeZ esa½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk,axsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3782(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price exclusive of local taxs, if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s. Ajanta

Pharma Limited.

TABLE

Sl.

Name of the Schedule Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated bilayered tablet contains

Telmisartan +

Telmisartan –40mg

1 Tablet

8.10

Metoprolol Tartrate

Metoprolol succinate – 23.75 mg eq. to

ER Tablet

Metoprolol Tartrate– 25 mg

(as extended release form)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO,2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3783¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk0vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh

izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ IysufV;l

QkekZL;wfVdy vkSj eSllZ ves¯tx fjlpZ ysc fyfeVsM fu£[email protected] fofufnZ"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ

gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd fQYe fyfir xksfy;ksa esa

lsfQfDle$

lsfQfDle VªkbZgkbMªsV

1 xksyh

15.88

,ftFkzksekbflu xksfy;ka

,UgkWbMªl lsfQfDle -200 fexzk- ds cjkcj

,ftFkzksekbflu MkbgkbMªsV

,UgkWbMªl ,ftFkzksekbflu-250 fexzk- ds cjkcj

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk,axsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3783(E).—In exercise of the powers, conferred by paragraphs 4, 11 and 14 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

prices as specified in column (5) of the Table hereto annexed as the retail price exclusive of local taxs , if any in relation to

each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s.

Plenteous Pharmaceuticals and M/s. Amazing Research Labs. Ltd.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each film coated tablet contains

Cefixime +

Cefixime as Trihydrate eq. to

1 Tablet

15.88

Azithromycin Tablet

Anhydrous cefixime – 200mg

Azithromycin as Dihydrate eq. to

Anhydrous Azithromycin – 250mg

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO,2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3784¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh

dk0vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr

'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn

,uihih, dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh

izfof"V;ksa esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ ;wuhesM VsDuksyksftl

fyfeVsM fu£[email protected] fofu£n"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i

esa fu;r djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd xksfy;ksa esa

oksxfycksl$fxykbeijkbM$

oksxfycksl-0.3 fexzk-

1 xksyh

10.46

esVQksjfeu ,plh,y xksfy;ka

fxykbeijkbM-2 fexzk-

¼Vªkboksfyc QksVZ 2 xksfy;ka½

esVQksjfeu ,plh,y-500 fexzk-

¼,DlVsUMsM fjfyt+ QkWeZ esa½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsaA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3784(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

price as specified in column (5) of the table hereto annexed as the retail price exclusive of local taxes, if any in relation to

each of the formulation specifed in the corresponding entry in column (2) of the said table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s.

Unimed Technologies Limited.

TABLE

Sl.

Name of the Schedule Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each tablet contains

Voglibose + Glimepiride

Voglibose – 0.3mg

1 Tablet

10.46

Metformin HCL Tablet

Metformin HCL – 500 mg

(Trivolib Forte 2)

(as extended Release)

Glimepiride – 2 mg

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO,2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production/import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3785¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0

vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa

dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼mlds ckn ,uihih,

dks Hkstk x;k gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa

esa fofufnZ"V izcyrk vkSj bdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ ;wuhesM VsDuksyksftl fyfeVsM

fu£[email protected] fofu£n"V fofufeZfr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r

djrh gSA

lkj.kh

Ø-la- vuqlwfpr fofufeZfr dk uke

izcyrk

bdkbZ

[kqnjk ewY;

¼#-½

izR;sd xksfy;ksa esa

oksxfycksl$fxykbeijkbM$

oksxfycksl-0.3 fexzk-

1 xksyh

8.47

esVQksjfeu ,plh,y xksfy;ka

fxykbeijkbM-1 fexzk-

¼Vªkboksfyc QksVZ 1 xksyh½

esVQksjfeu ,plh,y-500 fexzk-

¼,DlVsUMsM fjfyt+ QkWeZ esa½

uksV %

¼d½

fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh

ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½

vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g

ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA

¼x½

vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½

esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA

¼?k½

mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk

ls fHkUu vxj ekStwnk lEcfU/kr fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=k.k½ vkns'k]

2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls

,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼M-½

mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY;

fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k FkkA

¼p½

mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 2013

ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ

fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa

ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj

,uihih, dks izLrqr djsxkA

¼N½

fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkkfu;e]

1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼t½

bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r

gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi funs'kd

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

ORDER

New Delhi, the 20th December, 2013

S.O. 3785(E).—In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)

Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of

Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the

price as specified in column (5) of the table hereto annexed as the retail price exclusive of local taxes, if any in relation to

each of the formulations specified in the corresponding entry in column (2) of the said table with the strength and unit

specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by

M/s. Unimed Technologies Limited.

TABLE

Sl.

Name of the Scheduled Formulation

Strength

Unit

Retail Price

No.

(Rs.)

(1)

(2)

(3)

(4)

(5)

Each tablet contains

Voglibose + Glimepiride

Voglibose – 0.3mg

1 Tablet

8.47

Metformin HCL Tablet

Glimepiride – 1 mg

(Trivolib Forte 1)

Metformin HCL – 500 mg

(as extended Release)

Note :

(a)

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix

the retail price as specified in column (5) of the table hereinabove.

(b)

The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail

price mentioned in the column (5) of the above table.

(c)

The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance

with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the

DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)

Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above

table, launches a new drug as per paragraph 2 (u) of DPCO,2013 then he shall apply for prior price approval of such

new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.

(e)

The above mentioned non-ceiling price is applicable only to the individual manufacturers/marketer as mentioned

above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO,

2013.

(f)

The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its

production / import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturer, in case intending to

discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of

the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six

months prior to the indented date of discontinuation.

(g)

In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified

hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit

overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential

Commodities Act, 1955.

(h)

Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned

table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above

said date of notification, stand withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3786¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k us vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 1995 ds rgr dk-vk- 1492¼v½

fnukad 7.6.2013 ds f[kykQ eS- ,cksV bafM;k fyfeVsM ds fy, bC;wizksQsu ls lEcfU/kr fofufeZfr;ksa ds fy, vkS"k/k foHkkx }kjk tkjh

iqufoZyksdu vkns'k la- 31015/22/2013-ihvkbZ-I fnukad 03.12.2013 ij fn;s x;s vkns'k funsZ'kksa ds dk;kZUo;u gsrq jk"Vªh; vkS"k/k ewY;

fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 637¼v½ rkjh[k 4 flrEcj] 1997 ds lkFk ifBr

vkS"k/k ¼dher fu;a=k.k½ vkns'k] 1995 ds iSjk 9 ds mi iSjk ¼1½ vkSj ¼2½ }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj

ds jlk;u vkSj moZjd ea=kky; ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k la0 dk0 vk0 1492(v) fnukad 7.6.2013, dks tgk¡

rd mldk lEcU/k uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k

x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa

dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj iSd vkdkj lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] mRikn 'kqYd vkSj LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher vkSj LraHk ¼6½ esa fofufnZ"V

dher dh] mRikn 'kqYd] 'kSf{kd midj] fcØh dj@osV] ;fn dksbZ gS] dks lfEefyr dj vf/kdre [kqnjk dher ds :i esa fu;r djrh gSA

lkj.kh

Ø-la-

fofufeZfr dk uke

izcyrk

iSd vkdkj

vf/kdre dher

lHkh djksa lfgr

¼#-½

lerqY; vf/kdre

[kqnjk dher*

¼#-½

izR;sd fQYe fyfir fVfd;k esa

"1.

bC;wizksQsu xksfy;ka

bC;wizksQsu&200 fexzk-

10 dk iRrk@fCyLVj

3.77

4.09

bC;wizksQsu xksfy;ka

bC;wizksQsu&400 fexzk-

10 dk iRrk@fCyLVj

6.45

7.00

bC;wizksQsu xksfy;ka

bC;wizksQsu&600 fexzk-

10 dk iRrk@fCyLVj

9.25

10.04"

*ljdkjh mn~xzg.kksa@djksa ds okLrfod Hkqxrku dh 'krZ ij ykxw gSaA

uksV %

¼d½

tgka dgha Hkh gksyksxzke ds fy, #i;s 0.08 izfr iSd tSlk fd mi;qZDr LrEHk ¼4½ esa fn;k x;k gS mlesa vfrfjDr tksM+s tk,axsA

¼[k½

;s dhersa fofufnZ"V iSd o leku izcyrk ds iSdksa ij mRikn 'kqYd vkSj LFkkuh; dj dks lfEefyr dj LraHk ¼6½ esa vf/kdre

[kqnjk dher ds :i esa fu;r dh tkrh gSa] vkSj dEiuh fdlh NwV dk nkok ugha dj ldrh] tc rd mls NwV ds fy;s

ljdkj@jk-vkS-ew-fu-izk- ls vkns'k izkIr u gksaA

¼x½

dEifu;k¡@fofuekZrk dsoy rHkh dj tksM+ ldrs gSa ;fn mUgksaus LraHk (5) esa mfYyf[kr ewY; ij ljdkj dks okLro esa Hkqxrku

fd;k gSA ;fn vf/kdre [kqnjk ewY; ¼lHkh djksa lfgr½ esa dksbZ fofHkUurk gks rks og ,uihih, dks Mhihlhvks] 1995 ds QkWeZ&V

esa lwfpr fd;k tkuk pkfg,A

¼?k½

og iSd ftldh dEiksft'ku leku gS ysfdu vkdkj esa vUrj gS] og izks&jkVk izkbftax vkns'k dk- vk- 83¼v½ fnukad 27.1.1998

ds rgr xksfy;ka vkSj dSilwy ds iRrk@fCyLVj ds fy, vk;sxhA

¼M-½

mi;ksx dh xbZ fHkUu iSfdax lkexzh ;k fHkUu vkS"k/k forj.k iz.kkyh ;k nkok fd, x, fdlh vU; fo'ks"k :i ds fy,] tc rd

dEifu;k¡ buds QkWewZys'kuksa ds fy, fo'ks"khÑr ewY; vuqeksnuksa gsrq ,uihih, ds ikl ugha tkrh] mPpre ewY; tSls mDr

dkWye la- 5 esa fo'ks"khÑr gS] ykxw gksaxsA

¼p½

vkS"k/k ewY; fu;a=k.k vkns'k] 1995 ds rgr fu;r dh xbZ mDr dhersa lHkh [email protected] }kjk vko';d :i ls

ykxw djuh gksxh ftl rjg ls bu fofufeZfr iSd ij vkS"k/k ,oa izlk/ku vf/kfu;e] 1940 dh 'krs± ykxw gksrh gaSA

¼N½

mDr dfFkr fofufeZfr dh [email protected] dEiuh ds fy, vfuok;Z gS fd og mDr dfFkr fofufeZfr ds la?kVu esa fdlh

Hkh cnyko ds fy, ,uihih, dks fyf[kr iwoZ lwpuk ds lkFk l{ke izkf/kdkjh ls vko';d iwoZ vuqeksnu izkIr djsaA

¼t½

mDr ds vk/kkj ij fudkyh xbZ vf/kdre dher] mRikn 'kqYd vkSj osV dh orZeku njksa ds vuqlkj 1.0850 ds ?kVd }kjk

vf/kdre dher ls xq.kk djds vf/kdre [kqnjk dher ls vf/kd ugha gksxhA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼>½

mDr ds vuqlkj fudkyh xbZ vf/kdre [kqnjk dher] ;Fkk ykxw ljdkjh ysoh@djksa ds Hkqxrku dh 'krZ ds v/khu gS vkSj 1.0850

ds ?kVd esa t:jh lek;kstu] [email protected] dEiuh }kjk fd;k tkuk vko';d :i ls t:jh gS] tc dHkh mRikn 'kqYd

vkSj ;k osV dh orZeku nj esa cnyko gksrk gS] bl 'krZ ds v/khu fd bl izdkj ls x.kuk fd, x, mRikn 'kqYd vkSj ;k

osV] 1.0850 ds ?kVd ds vuqlkj [email protected] dEiuh ;k tSlh Hkh fLFkfr gks ds }kjk fdlh Hkh ekeys esa Hkqxrku fd,

x, okLrfod mRikn 'kqYd vkSj ;k osV ls vf/kd u gksA [email protected] dEiuh fo'ks"k :i ls bl 'krZ dk vuqikyu

lqfuf'pr djus ds fy, nk;h gksaxsA

(×k)Õ Õ Õ mDr lkj.kh esa O;kIr ugha gksus okys QkWewZys'ku@izcyrk ¼dEiksft'ku½ ftlesa LrEHk 3 ds fdlh Hkh vuqlwfpr vkS"k/k ds rRo

ekStwn gks] rks ;g lkj.kh ds lEcfU/kr Øe la[;k ds mPpre ewY; ds 'krZ ds v/khu gksxk tSlk ekeyk gks] tc rd fd fuekZrk

us blds i'pkr~ ml QkWewZys'ku ds fy, ,uihih, }kjk fu/kkZfjr fo'ks"khÑr ewY; izkIr ugha fd;k gksA

¼V½

fofuekZrk ;k foi.ku dEiuh] mDr dfFkr vf/klwpuk dh rkjh[k ls 15 fnuksa ds Hkhrj blesa n'kkZ;s mPpre ewY;ksa vkSj 'krks±

dk ikyu ugha djrh gSa rks] os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 1995 ds izko/kkuksa ds v/khu C;kt

lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼B½

bl vkns'k esa fofufeZr iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq,

gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3786(E).—In order to implement the directions given in review order no. 31015/22/2013-PI.I dated 03.12.2013

passed by the Department of Pharmaceuticals for M/s. Abbott India Ltd. against S.O. No. 1492(E) dated 07.06.2013 in

respect of Ibuprofen based formulations under DPCO 1995 and in exercise of the powers, conferred by sub-paragraphs (1)

and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997

issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the

Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No.

S.O. 1492(E), dated 7th June, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect

of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby

fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any,

and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each

of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and

pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Formulation

Strength

Pack Size

Ceiling Price

Equivalent MRP*

No.

(Rs.)

(inclusive of all

taxes)

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Each film coated tablet contains

“1.

Ibuprofen Tablets

Ibuprofen - 200 mg

10’s

3.77

4.09

Strip/Blister

Ibuprofen Tablets

Ibuprofen - 400 mg

10’s

6.45

7.00

Strip/Blister

Ibuprofen Tablets

Ibuprofen - 600 mg

10’s

9.25

10.04"

Strip/Blister

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)

Additional cost of Rs. 0.08 per pack specified in Column (4) of above table towards use of Hologram shall be added

wherever provided.

(b)

The prices fixed are the maximum retail prices in column (6) (inclcusive of excise duty and local taxes if any) for the

specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom,

unless specifically permitted by the Government/NPPA through an order.

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(c)

The companies/manufacturers may added taxes only if they have paid actually to the Government on the price

mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated

to the NPPA in the Form-V of DPCO, 1995.

(d)

Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated

27.1.1998 for tablet and capsule packed in strip/blister.

(e)

For different packing material used or, different drug delivery systems or any other special features/forms claimed,

the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA

for specific price approvals for its formulations.

(f)

The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by

the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation

pack under the Drugs and Cosmetics Act, 1940.

(g)

The manufacturer and marketing company for the above said formulation shall be required to take the requisite

prior approval from the competent Authority for any change in the composition of the above said formulation with

written prior intimation to the National Pharmaceutical Pricing Authority.

(h)

The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor

of 1.0850 as per the existing rates of excise duty and VAT.

(i)

The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary

adjustment in the factor of 1.0850 shall necessarily be required to be made by the manufacturer/marketing company,

whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise

duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/

marketing company or as applicable as per the factor of 1.0850. The manufacturer/marketing company shall be

specifically liable to ensure the compliance of this condition.

(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in

Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the

table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that

formulation.

(k)

The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes

hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount

along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

(l)

Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued

prior to this date of notification stand automatically withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3787¼v½.—jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k us vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 1995 ds rgr

dk-vk- 1495¼v½ fnukad 7.6.2013 ds f[kykQ eS- bidk fyfeVsM ds fy, ,fjFkzksekbflu ,LVksysV ls lEcfU/kr fofufeZfr;ksa ds fy,

vkS"k/k foHkkx }kjk tkjh iqufoZyksdu vkns'k la- 31015/12/2013-ihvkbZ-I fnukad 27.11.2013 ij fn;s x;s vkns'k funsZ'kksa ds dk;kZUo;u

gsrq jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk-vk- 637¼v½ rkjh[k 4 flrEcj]

1997 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½ vkns'k] 1995 ds iSjk 9 ds mi&iSjk ¼1½ vkSj ¼2½ }kjk iznRr 'kfDr;ksa dk iz;ksx djrs

gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k la- dk-vk- 1495¼v½ fnukad

7.6.2013, dks tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls

vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V dher dks mDr lkj.kh

ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj iSd vkdkj lfgr ml lkj.kh ds LraHk ¼2½ esa dh

rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] mRikn 'kqYd vkSj LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre

dher vkSj LraHk ¼6½ eas fofufnZ"V dher dh] mRikn 'kqYd] 'kSf{kd midj] fcØh dj@osV] ;fn dksbZ gS] dks lfEefyr dj vf/kdre [kqnjk

dher ds :i esa fu;r djrh gSA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

lkj.kh

Ø-

fofufeZfr dk uke

izcyrk

iSd vkdkj

vf/kdre

lHkh djksa lfgr

la-

dher

lerqY; vf/kdre

¼#-½

[kqnjk dher¹

¼#-½

izR;sd ?kqyu'khy fVfd;k esa

"1. ,fjFkzksekbflu

,fjFkzksekbflu ,LVksysV

10 dk

14.36

15.58

xksfy;ka

,fjFkzksekbflu&125 fexzk- ds cjkcj

,,y_iRrk

,fjFkzksekbflu

,fjFkzksekbflu ,LVksysV

10 dk

14.12

15.32

xksfy;ka

,fjFkzksekbflu&125 fexzk- ds cjkcj

,,y_fCyLVj

izR;sd fVfd;k esa

,fjFkzksekbflu

,fjFkzksekbflu ,LVksysV

10 dk

25.86

28.06

xksfy;ka

,fjFkzksekbflu&250 fexzk- ds cjkcj

iRrk@fCyLVj

,fjFkzksekbflu

,fjFkzksekbflu ,LVksysV

10 dk

50.36

54.64

xksfy;ka

,fjFkzksekbflu&500 fexzk- ds cjkcj

iRrk@fCyLVj

izR;sd 5 fefy esa

,fjFkzksekbflu

,fjFkzksekbflu ,LVksysV

60 fefy dk¡p dh

26.86

29.14"

lLisUlu

,fjFkzksekbflu&125 fexzk- ds cjkcj

cksry ,e-di vkSj

dkVZu lfgr

*ljdkjh mn~xzg.kksa@djksa ds okLrfod Hkqxrku dh 'krZ ij ykxw gSA

uksV %

¼d½

;s dhersa fofufnZ"V iSd o leku izcyrk ds iSdksa ij mRikn 'kqYd vkSj LFkkuh; dj dks lfEefyr dj LraHk ¼6½ esa vfèkdre

[kqnjk dher ds :i esa fu;r dh tkrh gSa] vkSj dEiuh fdlh NwV dk nkok ugha dj ldrh] tc rd mls NwV ds fy;s

ljdkj@jk-vkS-ew-fu-izk- ls vkns'k izkIr u gksaA

¼[k½

dEifu;k¡@fofuekZrk dsoy rHkh dj tksM+ ldrs gSa ;fn mUgksaus LraHk (5) esa mfYyf[kr ewY; ij ljdkj dks okLro esa Hkqxrku

fd;k gSA ;fn vf/kdre [kqnjk ewY; ¼lHkh djksa lfgr½ esa dksbZ fofHkUurk gks rks og ,uihih, dks Mhihlhvks] 1995 ds QkWeZ&V

esa lwfpr fd;k tkuk pkfg,A

¼x½

og iSd ftldh dEiksft'ku leku gS ysfdu vkdkj esa vUrj gS] og izks&jkVk izkbftax vkns'k dk- vk- 83¼v½ fnukad 27.1.1998

ds rgr xksfy;ka vkSj dSilwy ds iRrk@fCyLVj ds fy, vk;sxhA

¼?k½

mi;ksx dh xbZ fHkUu iSfdax lkexzh ;k fHkUu vkS"k/k forj.k iz.kkyh ;k nkok fd, x, fdlh vU; fo'ks"k :i ds fy,] tc rd

dEifu;k¡ buds QkWewZys'kuksa ds fy, fo'ks"khÑr ewY; vuqeksnuksa gsrq ,uihih, ds ikl ugha tkrh] mPpre ewY; tSls mDr

dkWye la- 5 esa fo'ks"khÑr gS] ykxw gksaxsA

¼³½

vkS"k/k ewY; fu;a=k.k vkns'k] 1995 ds rgr fu;r dh xbZ mDr dhersa lHkh [email protected] }kjk vko';d :i ls

ykxw djuh gksxh ftl rjg ls bu fofufeZfr iSd ij vkS"k/k ,oa izlk/ku vf/kfu;e] 1940 dh 'krs± ykxw gksrh gaSA

¼p½

mDr dfFkr fofufeZfr dh [email protected] dEiuh ds fy, vfuok;Z gS fd og mDr dfFkr fofufeZfr ds la?kVu esa fdlh

Hkh cnyko ds fy, ,uihih, dks fyf[kr iwoZ lwpuk ds lkFk l{ke izkf/kdkjh ls vko';d iwoZ vuqeksnu izkIr djsaA

¼N½

mDr ds vk/kkj ij fudkyh xbZ vf/kdre dher] mRikn 'kqYd vkSj osV dh orZeku njksa ds vuqlkj 1.0850 ds ?kVd }kjk

vf/kdre dher ls xq.kk djds vf/kdre [kqnjk dher ls vf/kd ugha gksxhA

¼t½

mDr ds vuqlkj fudkyh xbZ vf/kdre [kqnjk dher] ;Fkk ykxw ljdkjh ysoh@djksa ds Hkqxrku dh 'krZ ds v/khu gS vkSj 1.0850

ds ?kVd esa t:jh lek;kstu] [email protected] dEiuh }kjk fd;k tkuk vko';d :i ls t:jh gS] tc dHkh mRikn 'kqYd

vkSj ;k osV dh orZeku nj esa cnyko gksrk gS] bl 'krZ ds v/khu fd bl izdkj ls x.kuk fd, x, mRikn 'kqYd vkSj@;k

osV] 1.0850 ds ?kVd ds vuqlkj [email protected] dEiuh ;k tSlh Hkh fLFkfr gks ds }kjk fdlh Hkh ekeys esa Hkqxrku fd,

x, okLrfod mRikn 'kqYd vkSj ;k osV ls vf/kd u gksA [email protected] dEiuh fo'ks"k :i ls bl 'krZ dk vuqikyu

lqfuf'pr djus ds fy, nk;h gksaxsA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

¼>½

mDr lkj.kh esa O;kIr ugha gksus okys QkWewZys'ku@izcyrk ¼dEiksft'ku½ ftlesa LrEHk 3 ds fdlh Hkh vuqlwfpr vkS"k/k ds rRo

ekStwn gks] rks ;g lkj.kh ds lEcfU/kr Øe la[;k ds mPpre ewY; ds 'krZ ds v/khu gksxk tSlk ekeyk gks] tc rd fd fuekZrk

us blds i'pkr~ ml QkWewZys'ku ds fy, ,uihih, }kjk fu/kkZfjr fo'ks"khÑr ewY; izkIr ugha fd;k gksA

¼V½

fofuekZrk ;k foi.ku dEiuh] mDr dfFkr vf/klwpuk dh rkjh[k ls 15 fnuksa ds Hkhrj blesa n'kkZ;s mPpre ewY;ksa vkSj 'krks±

dk ikyu ugha djrh gSa rks] os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 1995 ds izko/kkuksa ds v/khu C;kt

lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼B½

bl vkns'k esa fofufeZr iSdksa dh vf/kdre dher fu;r gksus ds ifj.kke Lo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq,

gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3787(E).—In order to implement the directions given in review order no. 31015/12/2013-PL.I dated 27.11.2013

passed by the Department of Pharmaceuticals for M/s. IPCA Ltd. against S.O. No. 1495(E) dated 07.06.2013 in respect of

Erythromycin based formulations under DPCO 1995 and in exercise of the powers, conferred by sub-paragraphs (1) and (2)

of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4^th September, 1997 issued by

the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government

of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1495(E), dated

7^th June, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or

omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as

specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6)

of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled

formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified

respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the Formulation

Strength

Pack Size

Ceiling

Equivalent MRP*

No.

Price

(inclusive of all

(Rs.)

taxes) (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Each dispeersible tablet contains

“1.

Erythromycin

Erythromycin estolate eq. to

10’s Al_St

14.36

15.58

Tablets

Erythromycin - 125 mg

Erythromycin

Erythromycin estolate eq. to

10’s Al_Bl

14.12

15.32

Tablets

Erythromycin - 125 mg

Each tablet contains

Erythromycin

Erythromycin estolate eq. to

10’s

25.86

28.06

Tablets

Erythromycin - 250 mg

Strip/Blister

Erythromycin

Erythromycin estolate eq. to

10’s

50.36

54.64

Tablets

Erythromycin - 500 mg

Strip/Blister

Each 5ml contains

Erythromycin

Erythromycin Estolate

60 ml Glass

26.86

29.14”

Estolate Suspension

Eq. to Erythromycin 125mg

Bottle with

M. Cup & Carton

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)

The prices fixed are the maximum retail prices in column (6) (inclcusive of excise duty and local taxes if any) for the

specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom,

unless specifically permitted by the Government/NPPA through an order.

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

(b)

The companies / manufacturers may added taxes only if they have paid actually to the Government on the price

mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated

to the NPPA in the Form-V of DPCO, 1995.

(c)

Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated

27.1.1998 for tablet and capsule packed in strip/blister.

(d)

For different packing material used or, different drug delivery systems or any other special features/forms claimed,

the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA

for specific price approvals for its formulations.

(e)

The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by

the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation

pack under the Drugs and Cosmetics Act, 1940.

(f)

The manufacturer and marketing company for the above said formulation shall be required to take the requisite

prior approval from the competent Authority for any change in the composition of the above said formulation with

written prior intimation to the National Pharmaceutical Pricing Authority.

(g)

The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor

of 1.0850 as per the existing rates of excise duty and VAT.

(h)

The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable and necessary

adjustment in the factor of 1.0850 shall necessarily be required to be made by the manufacturer/marketing company,

whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise

duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/

marketing company or as applicable as per the factor of 1.0850. The manufacturer/marketing company shall be

specifically liable to ensure the compliance of this condition.

(i) Any other formulation / composition not covered in the above table that has any one of the scheduled drugs in

Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the

table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that

formulation.

(j)

The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes

hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount

along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

(k)

Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued

prior to this date of notification stand automatically withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3788¼v½.— jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k us vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 1995 ds rgr dk-vk- 1496¼v½

fnukad 7.6.2013 ds f[kykQ eSllZ ts-ch dsfedYl QkekZL;wfVdYl fyfeVsM vkSj eSllZ ysdj QkekZ fyfeVsM ds fy, eSVªksfuMkt+ksys

ls lEcfU/kr fofufeZfr;ksa ds fy, vkS"k/k foHkkx }kjk iqufoZyksdu vkns'k la- 31015/18/2013-ihvkbZ-I fnukad 27.11.2013 vkSj la- 31015/

17/2013-ihvkbZ-I fnukad 27.11.2013 ij fn;s x;s vkns'k funsZ'kksa ds dk;kZUo;u gsrq jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] Hkkjr

ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 637¼v½ rkjh[k 4 flrEcj] 1997 ds lkFk ifBr vkS"k/k ¼dher fu;a=k.k½

vkns'k] 1995 ds iSjk 9 ds mi iSjk ¼1½ vkSj ¼2½ }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd

ea=kky; ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k la0 dk0 vk0 1496(E) fnukad 7.6.2013, dks tgk¡ rd mldk lEcU/k uhps

dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk

yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ es dh Øe'k% rRLFkkuh

izfof"V;ksa esa fofufnZ"V izcyrk vkSj iSd vkdkj lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa

esa ls izR;sd dh] mRikn 'kqYd vkSj LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher vkSj LraHk ¼6½ esa fofufnZ"V dher dh]

mRikn 'kqYd] 'kSf{kd midj] fcØh dj@osV] ;fn dksbZ gS] dks lfEefyr dj vf/kdre [kqnjk dher ds :i esa fu;r djrh gSA

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

lkj.kh

Ø-la- fofufeZfr dk uke

izcyrk

iSd vkdkj

vf/kdre

lHkh djks

dher

lfgr lerqY;

¼#-½

vf/kdre

[kqnjk dher*

¼#-½

(1)

(2)

(3)

(4)

(5)

(6)

izR;sd fQYe fyfir fVfd;k esa

"1. eSVªksfuMkt+ksy xksfy;ka

eSVªksfuMkt+ksy&200 fexzk-

10 dk iRrk@fCyLVj

4.14

4.49

eSVªksfuMkt+ksy xksfy;ka

eSVªksfuMkt+ksy&400 fexzk-

10 dk iRrk@fCyLVj

7.32

7.94

eSVªksfuMkt+ksy$

eSVªksfuMkt+ksy&400 fexzk-

15 dk iRrk@fCyLVj

32.70

35.48

Mk;yksDlkukbM

Mk;yksDlkukbM ¶;wjsV&500 fexzk-

¶;wjsV xksfy;ka

eSVªksfuMkt+ksy$

eSVªksfuMkt+ksy&500 fexzk-

10 dk iRrk@fCyLVj

17.66

19.16

uksj¶yksDlhu xksfy;ka

uksj¶yksDlhu&400 fexzk-

izR;sd 5 fefy esa

eSVªksfuMkt+ksy$

eSVªksfuMkt+ksy csUtq,sV

60 fefy dk¡p

14.88

16.14

uksj¶yksDlhu

eSVªksfuMkt+ksy&100 fexzk- ds cjkcj

dh cksry

lLisUlu

uksj¶yksDlhu&100 fexzk-

,e di lfgr

eSVªksfuMkt+ksy

eSVªksfuMkt+ksy csUtq,sV

30 fefy dh isV

9.30

10.09

lLisUlu

eSVªksfuMkt+ksy&200 fexzk- ds cjkcj

cksry ,e di lfgr

eSVªksfuMkt+ksy

eSVªksfuMkt+ksy csUtq,sV

60 fefy dh isV

14.54

15.78

lLisUlu

eSVªksfuMkt+ksy&200 fexzk- ds cjkcj

cksry ,e di lfgr

izR;sd 100 fefy esa

eSVªksfuMkt+ksy

eSVªksfuMkt+ksy&500 fexzk-

100 fefy dh

12.34

13.39"

bUtSD'ku

IykfLVd cksry

*ljdkjh mn~xzg.kksa@djksa ds okLrfod Hkqxrku dh 'krZ ij ykxw gSaA

uksV %

¼d½

;s dhersa fofufnZ"V iSd o leku izcyrk ds iSdksa ij mRikn 'kqYd vkSj LFkkuh; dj dks lfEefyr dj LraHk ¼6½ esa vf/kdre

[kqnjk dher ds :i esa fu;r dh tkrh gSa] vkSj dEiuh fdlh NwV dk nkok ugha dj ldrh] tc rd mls NwV ds fy;s

ljdkj@jk-vkS-ew-fu-izk- ls vkns'k izkIr u gksaA

¼[k½

dEifu;k¡@fofuekZrk dsoy rHkh dj tksM+ ldrs gSa ;fn mUgksaus LraHk (5) esa mfYyf[kr ewY; ij ljdkj dks okLro esa Hkqxrku

fd;k gSA ;fn vf/kdre [kqnjk ewY; ¼lHkh djksa lfgr½ esa dksbZ fofHkUurk gks rks og ,uihih, dks Mhihlhvks] 1995 ds QkWeZ&V

esa lwfpr fd;k tkuk pkfg,A

¼x½

og iSd ftldh dEiksft'ku leku gS ysfdu vkdkj esa vUrj gS] og izks&jkVk izkbftax vkns'k dk- vk- 83¼v½ fnukad 27.1.1998

ds rgr xksfy;ka vkSj dSilwy ds iRrk@fCyLVj ds fy, vk;sxhA

¼?k½

mi;ksx dh xbZ fHkUu iSfdax lkexzh ;k fHkUu vkS"k/k forj.k iz.kkyh ;k nkok fd, x, fdlh vU; fo'ks"k :i ds fy,] tc rd

dEifu;k¡ buds QkWewZys'kuksa ds fy, fo'ks"khÑr ewY; vuqeksnuksa gsrq ,uihih, ds ikl ugha tkrh] mPpre ewY; tSls mDr

dkWye la- 5 esa fo'ks"khd`r gS] ykxw gksaxsA

¼³½

vkS"k/k ewY; fu;a=k.k vkns'k] 1995 ds rgr fu;r dh xbZ mDr dhersa lHkh [email protected] }kjk vko';d :i ls

ykxw djuh gksxh ftl rjg ls bu fofufeZfr iSd ij vkS"k/k ,oa izlk/ku vf/kfu;e] 1940 dh 'krs± ykxw gksrh gaSA

¼p½

mDr dfFkr fofufeZfr dh [email protected] dEiuh ds fy, vfuok;Z gS fd og mDr dfFkr fofufeZfr ds la?kVu esa fdlh

Hkh cnyko ds fy, ,uihih, dks fyf[kr iwoZ lwpuk ds lkFk l{ke izkf/kdkjh ls vko';d iwoZ vuqeksnu izkIr djsaA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼N½

mDr ds vk/kkj ij fudkyh xbZ vf/kdre dher] mRikn 'kqYd vkSj osV dh orZeku njksa ds vuqlkj 1.0850 ds ?kVd }kjk

vf/kdre dher ls xq.kk djds vf/kdre [kqnjk dher ls vf/kd ugha gksxhA

¼t½

mDr ds vuqlkj fudkyh xbZ vf/kdre [kqnjk dher] ;Fkk ykxw ljdkjh ysoh@djksa ds Hkqxrku dh 'krZ ds v/khu gS vkSj 1.0850

ds ?kVd esa t:jh lek;kstu] [email protected] dEiuh }kjk fd;k tkuk vko';d :i ls t:jh gS] tc dHkh mRikn 'kqYd

vkSj ;k osV dh orZeku nj esa cnyko gksrk gS] bl 'krZ ds v/khu fd bl izdkj ls x.kuk fd, x, mRikn 'kqYd vkSj ;k

osV] 1.0850 ds ?kVd ds vuqlkj [email protected] dEiuh ;k tSlh Hkh fLFkfr gks ds }kjk fdlh Hkh ekeys esa Hkqxrku fd,

x, okLrfod mRikn 'kqYd vkSj ;k osV ls vf/kd u gksA [email protected] dEiuh fo'ks"k :i ls bl 'krZ dk vuqikyu

lqfuf'pr djus ds fy, nk;h gksaxsA

¼>½

mDr lkj.kh esa O;kIr ugha gksus okys QkWewZys'ku@izcyrk ¼dEiksft'ku½ ftlesa LrEHk 3 ds fdlh Hkh vuqlwfpr vkS"k/k ds rRo

ekStwn gks] rks ;g lkj.kh ds lEcfU/kr Øe la[;k ds mPpre ewY; ds 'krZ ds v/khu gksxk tSlk ekeyk gks] tc rd fd fuekZrk

us blds i'pkr~ ml QkWewZys'ku ds fy, ,uihih, }kjk fu/kkZfjr fo'ks"khd`r ewY; izkIr ugha fd;k gksA

¼V½

fofuekZrk ;k foi.ku dEiuh] mDr dfFkr vf/klwpuk dh rkjh[k ls 15 fnuksa ds Hkhrj blesa n'kkZ;s mPpre ewY;ksa vkSj 'krks±

dk ikyu ugha djrh gSa rks] os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 1995 ds izko/kkuksa ds v/khu C;kt

lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼B½

bl vkns'k esa fofufeZr iSdksa dh vf/kdre dher fu;r gksus ds ifj.kke Lo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq,

gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi&funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3788(E).—In order to implement the directions given in review order no. 31015/18/2013-PI.I dated 27.11.2013

and no. 31015/17/2013-PI. I dated 27.11.2013 passed by the Department of Pharmaceuticals for M/s. J.B. Chemicals &

Pharmaceuticals Ltd. and M/s. Lekar Pharma Ltd. respectively against S.O. No. 1496(E) dated 07.06.2013 in respect of

Metronidazole based formulations under DPCO 1995 and in exercise of the powers, conferred by sub-paragraphs (1) and (2)

of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4^th September, 1997 issued by

the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of

India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1496(E), dated

7^th June, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or

omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as

specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of

the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled

formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified

respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the formulation

Strength

Pack

Ceiling

Equivalent

No.

Size

Price

MRP* (inclusive

(Rs.)

of all taxes)

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Each film coated tablet contains

“1.

Metronidazole Tablets

Metronidazole-200 mg

10’s Strip/Blister

4.14

4.49

Metronidazole Tablets

Metronidazole-400 mg

10’s Strip/Blister

7.32

7.94

Metronidazole +

Metronidazole-400 mg

15’s

32.70

35.48

Diloxanide Furoate

Diloxanide Furoate-500 mg

Strip/Blister

Tablets

Metronidazole +

Metronidazole-500 mg

10’s

17.66

19.16

Norfloxacin Tablets

Norfloxacin-400 mg

Strip/Blister

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

Each 5ml contains

Metronidazole+

Metronidazole Benzoate eq.

60 ml Glass

14.88

16.14

Norfloxacin

to Metronidazole - 100 mg

Bottle with

Suspension

Norfloxacin - 100 mg

M. Cup

Metronidazole

Metronidazole Benzoate eq.

30 ml Pet

9.30

10.09

Suspension

to Metronidazole - 200 mg

Bottle with

M. Cup

Metronidazole

Metronidazole Benzoate eq.

60 ml Pet

14.54

15.78

Suspension

to Metronidazole - 200 mg

Bottle with

M. Cup

Each 100ml contains

Metronidazole

Metronidazole -500 mg

100 ml

12.34

13.39"

Injection

Plastic Bottle

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)

The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the

specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom,

unless specifically permitted by the Government/NPPA through an order.

(b)

The companies/manufacturers may added taxes only if they have paid actually to the Government on the price

mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated

to the NPPA in the Form-V of DPCO, 1995.

(c)

Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated

27.1.1998 for tablet and capsule packed in strip/blister.

(d)

For different packing material used or, different drug delivery systems or any other special features/forms claimed,

the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA

for specific price approvals for its formulations.

(e)

The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by

the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation

pack under the Drugs and Cosmetics Act, 1940.

(f)

The manufacturer and marketing company for the above said formulation shall be required to take the requisite

prior approval from the competent Authority for any change in the composition of the above said formulation with

written prior intimation to the National Pharmaceutical Pricing Authority.

(g)

The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor

of 1.0850 as per the existing rates of excise duty and VAT.

(h)

The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary

adjustment in the factor of 1.0850 shall necessarily be required to be made by the manufacturer/marketing company,

whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise

duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/

marketing company or as applicable as per the factor of 1.0850. The manufacturer/marketing company shall be

specifically liable to ensure the compliance of this condition.

(i)

Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in

Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the

table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that

formulation.

(j)

The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes

hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount

along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

(k)

Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued

prior to this date of notification stand automatically withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

(1)

(2)

(3)

(4)

(5)

(6)

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3789¼v½.— jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k us vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 1995 ds rgr dk-vk- 1497¼v½

fnukad 7.6.2013 ds f[kykQ eS- Y;wfiu fyfeVsM ds fy, fjQSEihflu ls lEcfU/kr fofufeZfr;ksa ds fy, vkS"k/k foHkkx }kjk tkjh

iqufoZyksdu vkns'k la- 31015/11/2013-ihvkbZ-I fnukad 27.11.2013 ij fn;s x;s vkns'k funsZ'kksa ds dk;kZUo;u gsrq jk"Vªh; vkS"k/k ewY;

fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 637¼v½ rkjh[k 4 flrEcj] 1997 ds lkFk ifBr

vkS"k/k ¼dher fu;a=k.k½ vkns'k] 1995 ds iSjk 9 ds mi iSjk ¼1½ vkSj ¼2½ }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj

ds jlk;u vkSj moZjd ea=kky; ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k la0 dk0 vk0 1497(v) fnukad 7.6.2013, dks tgk¡

rd mldk lEcU/k uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k

x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas

dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj iSd vkdkj lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh] mRikn 'kqYd vkSj LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher vkSj LraHk ¼6½ esa

fofufnZ"V dher dh] mRikn 'kqYd] 'kSf{kd midj] fcØh dj@osV] ;fn dksbZ gS] dks lfEefyr dj vf/kdre [kqnjk dher ds :i

esa fu;r djrh gSA

lkj.kh

Ø-la- fofufeZfr dk uke

izcyrk

iSd vkdkj

vf/kdre

lHkh djkas

dher

lfgr lerqY;

¼#-½

vf/kdre

[kqnjk dher*

¼#-½

izR;sd dSilwy esa

"1.

fjQSEihflu dSilwy

fjQSEihflu&150 fexzk-

10 dk iRrk@fCyLVj

17.54

19.03

fjQSEihflu dSilwy

fjQSEihflu&300 fexzk-

10 dk iRrk@fCyLVj

31.68

34.37

fjQSEihflu dSilwy

fjQSEihflu&450 fexzk-

10 dk iRrk@fCyLVj

45.92

49.82

fjQSEihflu dSilwy

fjQSEihflu&600 fexzk-

10 dk iRrk@fCyLVj

60.62

65.77

fjQSEihflu$

fjQSEihflu&450 fexzk-

10 dk iRrk@fCyLVj

49.34

53.53

vkblksfu;kft+M

vkblksfu;kft+M&300 fexzk-

dSilwy

izR;sd ?kqyu'khy fVfd;k esa

fjQSEihflu$

fjQSEihflu&60 fexzk-

6 dk

4.90

5.32

vkblksfu;kft+M

vkblksfu;kft+M&30 fexzk-

,,y_iRrk

xksfy;ka

fjQSEihflu$

fjQSEihflu&60 fexzk-

6 dk

4.76

5.16

vkblksfu;kft+M

vkblksfu;kft+M&30 fexzk-

,,y_fCyLVj

xksfy;ka

fjQSEihflu$

fjQSEihflu&100 fexzk-

10 dk

11.66

12.65

vkblksfu;kft+M

vkblksfu;kft+M&50 fexzk-

iRrk@fCyLVj

xksfy;ka

fjQSEihflu$

fjQSEihflu&100 fexzk-

10 dk ,Y;w ,Y;w

12.50

13.56

vkblksfu;kft+M

vkblksfu;kft+M&50 fexzk-

iRrk@fCyLVj

xksfy;ka

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

10.

fjQSEihflu$

fjQSEihflu&100 fexzk-

10 dk

13.40

14.54

vkblksfu;kft+M

vkblksfu;kft+M&100 fexzk-

,,y_iRrk

xksfy;ka

11.

fjQSEihflu$

fjQSEihflu&100 fexzk-

10 dk

13.04

14.15

vkblksfu;kft+M

vkblksfu;kft+M&100 fexzk-

,,y_fCyLVj

xksfy;ka

12.

fjQSEihflu$

fjQSEihflu&100 fexzk-

10 dk

20.42

22.16

vkblksfu;kft+M$

vkblksfu;kft+M&50 fexzk-

,,y_iRrk

ik;jkftukekbM

ik;jkftukekbM&300 fexzk-

xksfy;ka

13.

fjQSEihflu$

fjQSEihflu&150 fexzk-

10 dk

29.62

32.14

vkblksfu;kft+M$

vkblksfu;kft+M&100 fexzk-

,,y_iRrk

ik;jkftukekbM

ik;jkftukekbM&500 fexzk-

xksfy;ka

14.

fjQSEihflu$

fjQSEihflu&150 fexzk-

10 dk

29.04

31.51

vkblksfu;kft+M$

vkblksfu;kft+M&100 fexzk-

,,y_fCyLVj

ik;jkftukekbM

ik;jkftukekbM&500 fexzk-

xksfy;ka

15.

fjQSEihflu$

fjQSEihflu&60 fexzk-

6 dk

7.36

7.99

vkblksfu;kft+M$

vkblksfu;kft+M&30 fexzk-

,,y_iRrk

ik;jkftukekbM

ik;jkftukekbM&150 fexzk-

xksfy;ka

16.

fjQSEihflu$

fjQSEihflu&60 fexzk-

6 dk

7.12

7.73

vkblksfu;kft+M$

vkblksfu;kft+M&30 fexzk-

,,y_fCyLVj

ik;jkftukekbM

ik;jkftukekbM&150 fexzk-

xksfy;ka

izR;sd fQYe fyfir fVfd;k esa

17.

fjQSEihflu$

fjQSEihflu&150 fexzk-

6 dk iRrk@fCyLVj

10.72

11.63

vkblksfu;kft+M

vkblksfu;kft+M&75 fexzk-

xksfy;ka

18.

fjQSEihflu$

fjQSEihflu&150 fexzk-

6 dk ,,y_ihohMhlh@

10.96

11.89

vkblksfu;kft+M

vkblksfu;kft+M&75 fexzk-

ihohlh fQYe fCyLVj

xksfy;ka

19.

fjQSEihflu$

fjQSEihflu&225 fexzk-

10 dk iRrk@fCyLVj

42.02

45.59

vkblksfu;kft+M$

vkblksfu;kft+M&150 fexzk-

ik;jkftukekbM

ik;jkftukekbM&750 fexzk-

xksfy;ka

20.

fjQSEihflu$

fjQSEihflu&225 fexzk-

10 dk ,,y_ihohMhlh@

42.66

46.29

vkblksfu;kft+M$

vkblksfu;kft+M&150 fexzk-

ihohlh fQYe fCyLVj

ik;jkftukekbM

ik;jkftukekbM&750 fexzk-

xksfy;ka

21.

fjQSEihflu$

fjQSEihflu&150 fexzk-

10 dk ,,y_iRrk

28.92

31.38

vkblksfu;kft+M$

vkblksfu;kft+M&75 fexzk-

bFkkeC;wVksy

bFkkeC;wVksy ,plh,y&275 fexzk-

xksfy;ka

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

22.

fjQSEihflu$

fjQSEihflu&150 fexzk-

10 dk ,,y_ihohMhlh@

29.56

32.07

vkblksfu;kft+M$

vkblksfu;kft+M&75 fexzk-

ihohlh fQYe fCyLVj

bFkkeC;wVksy

bFkkeC;wVksy ,plh,y&275 fexzk-

xksfy;ka

23.

fjQSEihflu$

fjQSEihflu&450 fexzk-

6 dk ,,y_ihohMhlh@

47.72

51.78

vkblksfu;kft+M$

vkblksfu;kft+M&300 fexzk-

ihohlh fQYe fCyLVj

bFkkeC;wVksy

bFkkeC;wVksy ,plh,y&800 fexzk-

xksfy;ka

24.

fjQSEihflu$

fjQSEihflu&150 fexzk-

10 dk ,,y_ihohMhlh@

39.12

42.45

vkblksfu;kft+M$

vkblksfu;kft+M&75 fexzk-

ihohlh fQYe fCyLVj

ik;jkftukekbM$

ik;jkftukekbM&400 fexzk-

bFkkeC;wVksy xksfy;ka

bFkkeC;wVksy ,plh,y&275 fexzk-

25.

fjQSEihflu$

fjQSEihflu&225 fexzk-

6 dk iRrk@fCyLVj

35.48

38.50

vkblksfu;kft+M$

vkblksfu;kft+M&150 fexzk-

ik;jkftukekbM$

ik;jkftukekbM&750 fexzk-

bFkkeC;wVksy xksfy;ka

bFkkeC;wVksy ,plh,y&400 fexzk-

26.

fjQSEihflu$

fjQSEihflu&150 fexzk-

3 dk iRrk@fCyLVj

12.72

13.80

vkblksfu;kft+M$

vkblksfu;kft+M&100 fexzk-

ik;jkftukekbM$

ik;jkftukekbM&500 fexzk-

bFkkeC;wVksy xksfy;ka

bFkkeC;wVksy ,plh,y&267 fexzk-

27.

fjQSEihflu$

fjQSEihflu&450 fexzk-

10 dk ,,y_iRrk

51.38

55.75

vkblksfu;kft+M

vkblksfu;kft+M&300 fexzk-

xksfy;ka

28.

fjQSEihflu$

fjQSEihflu&450 fexzk-

10 dk ,,y_ihohMhlh@

51.88

56.29

vkblksfu;kft+M

vkblksfu;kft+M&300 fexzk-

ihohlh fQYe fCyLVj

xksfy;ka

29.

fjQSEihflu$

fjQSEihflu&600 fexzk-

10 dk iRrk@fCyLVj

64.14

69.59

vkblksfu;kft+M

vkblksfu;kft+M&300 fexzk-

xksfy;ka

30.

fjQSEihflu$

fjQSEihflu&600 fexzk-

10 dk ,,y_ihohMhlh@

64.78

70.29

vkblksfu;kft+M

vkblksfu;kft+M&300 fexzk-

ihohlh fQYe fCyLVj

xksfy;ka

izR;sd fdV esa

31.

fjQSEihflu$

fjQSEihflu&450 fexzk-

2 dk fdV

8.36

9.07

vkblksfu;kft+M$

dk 1 dSilwy

¼1 dSilwy$1 xksyh½

bFkkeC;wVksy

bFkkeC;wVksy&800 fexzk- vkSj

xksfy;ka

vkblksfu;kft+M&300 fexzk- dh 1 xksyh

32.

fjQSEihflu$

fjQSEihflu&450 fexzk-

4 dk fdV

12.14

13.17

vkblksfu;kft+M$

dk 1 dSilwy

¼1 dSilwy$3 xksyh½

bFkkeC;wVksy$

bFkkeC;wVksy&800 fexzk- vkSj

ik;jkftukekbM

vkblksfu;kft+M&300 fexzk- dh 1 xksyh

xksfy;ka

ik;jkftukekbM&750 fexzk- dh 2 xksyh

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

33.

fjQSEihflu$

izR;sd fQYe fyfir fVfd;k esa

10×4 dk

143.70

155.91

vkblksfu;kft+M$

fjQSEihflu&600 fexzk-

,,y_ihohMhlh@

bFkkeC;wVksy$

vkblksfu;kft+M&300 fexzk-

ihohlh fQYe fCyLVj

ik;jkftukekbM

izR;sd fVfd;k esa

xksfy;ka

ik;jkftukekbM&800 fexzk- dh

¼2 xksfy;ka½ bFkkeC;wVksy&1100 fexzk-

izR;sd 5 fefy esa

34.

fjQSEihflu

fjQSEihflu&100 fexzk-

200 fefy dk¡p dh

64.90

70.42"

lLisUlu

cksry ,e- di lfgr

*ljdkjh mn~xzg.kksa@djksa ds okLrfod Hkqxrku dh 'krZ ij ykxw gSaA

uksV %

¼d½

;s dhersa fofufnZ"V iSd o leku izcyrk ds iSdksa ij mRikn 'kqYd vkSj LFkkuh; dj dks lfEefyr dj LraHk ¼6½ eas vf/kdre

[kqnjk dher ds :i esa fu;r dh tkrh gSa] vkSj dEiuh fdlh NwV dk nkok ugha dj ldrh] tc rd mls NwV ds fy;s

ljdkj@jk-vkS-ew-fu-izk- ls vkns'k izkIr u gksaA

¼[k½

dEifu;k¡@fofuekZrk dsoy rHkh dj tksM+ ldrs gSa ;fn mUgksaus LraHk (5) esa mfYyf[kr ewY; ij ljdkj dks okLro esa Hkqxrku

fd;k gSA ;fn vf/kdre [kqnjk ewY; ¼lHkh djksa lfgr½ esa dksbZ fofHkUurk gks rks og ,uihih, dks Mhihlhvks] 1995 ds QkWeZ&V

esa lwfpr fd;k tkuk pkfg,A

¼x½

og iSd ftldh dEiksft'ku leku gS ysfdu vkdkj esa vUrj gS] og izks&jkVk izkbftax vkns'k dk- vk- 83¼v½ fnukad 27.1.1998

ds rgr xksfy;ka vkSj dSilwy ds iRrk@fCyLVj ds fy, vk;sxhA

¼?k½

mi;ksx dh xbZ fHkUu iSfdax lkexzh ;k fHkUu vkS"k/k forj.k iz.kkyh ;k nkok fd, x, fdlh vU; fo'ks"k :i ds fy,] tc rd

dEifu;k¡ buds QkWewZys'kuksa ds fy, fo'ks"khÑr ewY; vuqeksnuksa gsrq ,uihih, ds ikl ugha tkrh] mPpre ewY; tSls mDr

dkWye la- 5 esa fo'ks"khÑr gS] ykxw gksaxsA

¼M-½

vkS"k/k ewY; fu;a=k.k vkns'k] 1995 ds rgr fu;r dh xbZ mDr dhersa lHkh [email protected] }kjk vko';d :i ls

ykxw djuh gksxh ftl rjg ls bu fofufeZfr iSd ij vkS"k/k ,oa izlk/ku vf/kfu;e] 1940 dh 'krs± ykxw gksrh gaSA

¼p½

mDr dfFkr fofufeZfr dh [email protected] dEiuh ds fy, vfuok;Z gS fd og mDr dfFkr fofufeZfr ds la?kVu esa fdlh

Hkh cnyko ds fy, ,uihih, dks fyf[kr iwoZ lwpuk ds lkFk l{ke izkf/kdkjh ls vko';d iwoZ vuqeksnu izkIr djsaA

¼N½

mDr ds vk/kkj ij fudkyh xbZ vf/kdre dher] mRikn 'kqYd vkSj osV dh orZeku njksa ds vuqlkj 1.0850 ds ?kVd }kjk

vf/kdre dher ls xq.kk djds vf/kdre [kqnjk dher ls vf/kd ugha gksxhA

¼t½

mDr ds vuqlkj fudkyh xbZ vf/kdre [kqnjk dher] ;Fkk ykxw ljdkjh ysoh@djksa ds Hkqxrku dh 'krZ ds v/khu gS vkSj 1.0850

ds ?kVd esa t:jh lek;kstu] [email protected] dEiuh }kjk fd;k tkuk vko';d :i ls t:jh gS] tc dHkh mRikn 'kqYd

vkSj ;k osV dh orZeku nj esa cnyko gksrk gS] bl 'krZ ds v/khu fd bl izdkj ls x.kuk fd, x, mRikn 'kqYd vkSj ;k

osV] 1.0850 ds ?kVd ds vuqlkj [email protected] dEiuh ;k tSlh Hkh fLFkfr gks ds }kjk fdlh Hkh ekeys esa Hkqxrku fd,

x, okLrfod mRikn 'kqYd vkSj ;k osV ls vf/kd u gksA [email protected] dEiuh fo'ks"k :i ls bl 'krZ dk vuqikyu

lqfuf'pr djus ds fy, nk;h gksaxsA

¼>½

mDr lkj.kh esa O;kIr ugha gksus okys QkWewZys'ku@izcyrk¼dEiksft'ku½ ftlesa LrEHk 3 ds fdlh Hkh vuqlwfpr vkS"k/k ds rRo

ekStwn gks] rks ;g lkj.kh ds lEcfU/kr Øe la[;k ds mPpre ewY; ds 'krZ ds v/khu gksxk tSlk ekeyk gks] tc rd fd fuekZrk

us blds i'pkr~ ml QkWewZys'ku ds fy, ,uihih, }kjk fu/kkZfjr fo'ks"khÑr ewY; izkIr ugha fd;k gksA

¼V½

fofuekZrk ;k foi.ku dEiuh] mDr dfFkr vf/klwpuk dh rkjh[k ls 15 fnuksa ds Hkhrj blesa n'kkZ;s mPpre ewY;ksa vkSj 'krks±

dk ikyu ugha djrh gSa rks] os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 1995 ds izko/kkuksa ds v/khu C;kt

lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

¼B½

bl vkns'k esa fofufeZr iSdksa dh vf/kdre dher fu;r gksus ds ifj.kke Lo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq,

gS] Lor% gh fujLr gks tk;saxsaA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3789(E).—In order to implement the directions given in review order no. 31015/11/2013-PI.I dated 27.11.2013

passed by the Department of Pharmaceuticals for M/s Lupin Ltd. against S.O. No. 1497(E) dated 07.06.2013 in respect of

Rifampicin based formulations under DPCO 1995 and in exercise of the powers, conferred by sub-paragraphs (1) and (2) of

paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the

Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of

India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1497(E), dated

7th June, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or

omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as

specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of

the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled

formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified

respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the formulation

Strength

Pack

Ceiling

Equivalent

No.

Size

Price

MRP*(inclusive

(Rs.)

of all taxes)

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Each Capsule contains

“1.

Rifampicin Capsule

Rifampicin -150 mg

10’s Strip/Blister

17.54

19.03

Rifampicin Capsule

Rifampicin -300 mg

10’s Strip/Blister

31.68

34.37

Rifampicin Capsule

Rifampicin -450 mg

10’s Strip/Blister

45.92

49.82

Rifampicin Capsule

Rifampicin -600 mg

10’s Strip/Blister

60.62

65.77

Rifampicin+

Rifampicin -450mg

10’s

49.34

53.53

Isoniazid Capsule

Isoniazide -300mg

Strip/Blister

Each dispersible tablet contains

Rifampicin+

Rifampicin - 60mg

6’s

4.90

5.32

Isoniazide Tablets

Isoniazide - 30mg

Al_Strip

Rifampicin+

Rifampicin - 60mg

6’s

4.76

5.16

Isoniazide Tablets

Isoniazide - 30mg

Al_Blister

Rifampicin+

Rifampicin - 100 mg

10’s

11.66

12.65

Isoniazide Tablets

Isoniazide - 50 mg

Strip/Blister

Rifampicin+

Rifampicin - 100 mg

10’s Alu_Alu

12.50

13.56

Isoniazide Tablets

Isoniazide - 50 mg

Strip/Blister

10.

Rifampicin+

Rifampicin - 100 mg

10’s

13.40

14.54

Isoniazide Tablets

Isoniazide - 100 mg

Al_Strip

11.

Rifampicin+

Rifampicin - 100 mg

10’s

13.04

14.15

Isoniazide Tablets

Isoniazide - 100 mg

Al_ Blister

12.

Rifampicin+

Rifampicin - 100 mg

10’s

20.42

22.16

Isoniazide+

Isoniazid - 50 mg

Al_Strip

Pyrazinamide Tablets

Pyrazinamide - 300mg

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

13.

Rifampicin+

Rifampicin - 150 mg

10’s

29.62

32.14

Isoniazide+

Isoniazide - 100 mg

Al_Strip

Pyrazinamide Tablets

Pyrazinamide - 500mg

14.

Rifampicin+

Rifampicin - 150 mg

10’s

29.04

31.51

Isoniazide+

Isoniazide - 100 mg

Al_Blister

Pyrazinamide Tablets

Pyrazinamide - 500mg

15.

Rifampicin+

Rifampicin - 60 mg

6’s

7.36

7.99

Isoniazide+

Isoniazide - 30 mg

Al_Strip

Pyrazinamide Tablets

Pyrazinamide - 150mg

16.

Rifampicin+

Rifampicin - 60 mg

6’s

7.12

7.73

Isoniazide+

Isoniazide - 30 mg

Al_Blister

Pyrazinamide Tablets

Pyrazinamide - 150mg

Each film coated tablet contains

17.

Rifampicin+

Rifampicin - 150 mg

6’s

10.72

11.63

Isoniazide Tablets

Isoniazide - 75 mg

Strip/Blister

18.

Rifampicin+

Rifampicin - 150 mg

6’s Al_PVDC/

10.96

11.89

Isoniazide Tablets

Isoniazide - 75 mg

PVC Film Blister

19.

Rifampicin+

Rifampicin - 225 mg

10’s

42.02

45.59

Isoniazid+

Isoniazide - 150 mg

Strip/Blister

Pyrazinamide Tablets

Pyrazinamide - 750 mg

20.

Rifampicin+

Rifampicin - 225 mg

10’s Al_PVDC/

42.66

46.29

Isoniazid+

Isoniazide - 150 mg

PVC Film Blister

Pyrazinamide Tablets

Pyrazinamide - 750 mg

21.

Rifampicin+

Rifampicin - 150 mg

10’s

28.92

31.38

Isoniazide+

Isoniazide - 75 mg

Al_Strip

Ethambutol Tablets

Ethambutol HCl - 275 mg

22.

Rifampicin+

Rifampicin - 150 mg

10’s Al_PVDC/

29.56

32.07

Isoniazide+

Isoniazide - 75 mg

PVC Film Blister

Ethambutol Tablets

Ethambutol HCl - 275 mg

23.

Rifampicin+

Rifampicin - 450 mg

6’s

47.72

51.78

Isoniazide+

Isoniazide - 300 mg

Strip/Blister

Ethambutol Tablets

Ethambutol HCl - 800 mg

24.

Rifampicin+

Rifampicin - 150 mg

10’s Al_PVDC/

39.12

42.45

Isoniazide+

Isoniazide - 75 mg

PVC Film Blister

Pyrazinamide+

Pyrazinamide - 400 mg

Ethambutol Tablets

Ethambutol HCl - 275 mg

25.

Rifampicin+

Rifampicin - 225 mg

6’s Al_PVDC/

35.48

38.50

Isoniazide+

Isoniazide - 150 mg

PVC Film Blister

Pyrazinamide+

Pyrazinamide - 750 mg

Ethambutol Tablets

Ethambutol HCl - 400 mg

26.

Rifampicin+

Rifampicin - 150 mg

3’s

12.72

13.80

Isoniazide+

Isoniazide -100 mg

Strip/Blister

Pyrazianamide+

Pyrazianamide - 500mg

Ethambutol Tablets

Ethambutol HCl - 267mg

27.

Rifampicin+

Rifampicin 450mg

10’s

51.38

55.75

Isoniazide Tablets

Isoniazide 300mg

Al_Strip

28.

Rifampicin+

Rifampicin 450mg

10’s Al_PVDC/

51.88

56.29

Isoniazide Tablets

Isoniazide 300mg

PVC Film Blister

29.

Rifampicin+

Rifampicin 600mg

10’s Strip/Blister

64.14

69.59

Isoniazide Tablets

Isoniazide 300mg

(1)

(2)

(3)

(4)

(5)

(6)

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

30.

Rifampicin+

Rifampicin 600mg

10’s Al_PVDC/

64.78

70.29

Isoniazide Tablets

Isoniazide 300mg

PVC Film Blister

Each Kit Contains

31.

Rifampicin+

1 capsule of Rifampicin-450mg

2’s Kit

8.36

9.07

Isoniazid+

1 tablet of Ethambutol-800mg

(1 Cap +

Ethambutol Tablets

& Isoniazide 300mg

1 Tab.)

32.

Rifampicin+

1 capsule of Rifampicin-450mg

4’s Kit

12.14

13.17

Isoniazid+

1 tablet of Ethambutol 800mg

(1 Cap.+

Ethambutol+

& Isoniazide 300mg

3 Tab.)

Pyrazinamide Tablets

2 tablet of Pyrazinamide-750mg

33.

Rifampicin+

Each film coated tab contains

10x4’s Al_

143.70

155.91

Isoniazide+

Rifampicin 600mg

PVDC/PVC

Pyrazinamide+

Isoniazide 300mg

Film Blister

Ethambutol Tablets

Each tablet contain

Pyrazinamide-800 mg (2 tablet )

Ethambutol - 1100 mg

Each 5ml contains

34.

Rifampicin

Rifampicin-100mg

200 ml Glass

64.90

70.42"

Suspension

Bottle with

M. Cup

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)

The prices fixed are the maximum retail prices in column (6) (inclcusive of excise duty and local taxes if any) for the

specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom,

unless specifically permitted by the Government/NPPA through an order.

(b)

The companies / manufacturers may added taxes only if they have paid actually to the Government on the price

mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated

to the NPPA in the Form-V of DPCO, 1995.

(c)

Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated

27.1.1998 for tablet and capsule packed in strip/blister.

(d)

For different packing material used or, different drug delivery systems or any other special features/forms claimed,

the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA

for specific price approvals for its formulations.

(e)

The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by

the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation

pack under the Drugs and Cosmetics Act, 1940.

(f)

The manufacturer and marketing company for the above said formulation shall be required to take the requisite

prior approval from the competent Authority for any change in the composition of the above said formulation with

written prior intimation to the National Pharmaceutical Pricing Authority.

(g)

The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor

of 1.0850 as per the existing rates of excise duty and VAT.

(h)

The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable and necessary

adjustment in the factor of 1.0850 shall necessarily be required to be made by the manufacturer/marketing company,

whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise

duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/

marketing company or as applicable as per the factor of 1.0850. The manufacturer/marketing company shall be

specifically liable to ensure the compliance of this condition.

(i)

Any other formulation / composition not covered in the above table that has any one of the scheduled drugs in

Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the

table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that

formulation.

(1)

(2)

(3)

(4)

(5)

(6)

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

(j)

The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes

hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount

along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

(k)

Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued

prior to this date of notification stand automatically withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

vkns'k

ubZ fnYyh] 20 fnlEcj] 2013

dk-vk- 3790¼v½.— jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k us vkS"k/k ¼ewY; fu;a=k.k½ vkns'k] 1995 ds rgr dk-vk- 1498¼v½

fnukad 7.6.2013 ds f[kykQ eS- bidk fyfeVsM ds fy, DyksjksDohu QksLQsV ls lEcfU/kr fofufeZfr;ksa ds fy, vkS"k/k foHkkx }kjk tkjh

iqufoZyksdu vkns'k la- 31015/19/2013-ihvkbZ-I fnukad 27.11.2013 ij fn;s x;s vkns'k funsZ'kksa ds dk;kZUo;u gsrq jk"Vªh; vkS"k/k ewY;

fu/kkZj.k izkf/kdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 637¼v½ rkjh[k 4 flrEcj] 1997 ds lkFk ifBr

vkS"k/k ¼dher fu;a=k.k½ vkns'k] 1995 ds iSjk 9 ds mi&iSjk ¼1½ vkSj ¼2½ }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj

ds jlk;u vkSj moZjd ea=kky; ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k la0 dk0 vk0 1498(E) fnukad 7.6.2013, dks tgk¡

rd mldk lEcU/k uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k

x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa

dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj iSd vkdkj lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V

vuqlwfpr fofufeZr;ksa esa ls izR;sd dh] mRikn 'kqYd vkSj LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher vkSj LraHk ¼6½ eas

fofufnZ"V dher dh] mRikn 'kqYd] 'kSf{kd midj] fcØh dj@osV] ;fn dksbZ gS] dks lfEefyr dj vf/kdre [kqnjk dher ds :i

esa fu;r djrh gSA

lkj.kh

Ø-la- fofufeZfr dk uke

izcyrk

iSd vkdkj

vf/kdre

lHkh djkas

dher

lfgr lerqY;

¼#-½

vf/kdre

[kqnjk dher*

¼#-½

izR;sd fQYe fyfir fVfd;k esa

"1. DyksjksDohu xksfy;ka

DyksjksDohu QksLQsV&250 fexzk-

10 dk iRrk@fCyLVj

7.14

7.75

DyksjksDohu xksfy;ka

DyksjksDohu QksLQsV&250 fexzk-

5 dk iRrk@fCyLVj

6.94

7.53

izR;sd 5 fefy esa

DyksjksDohu

DyksjksDohu QksLQsV

60 fefy dh

16.64

18.05

lLisUlu

DyksjksDohu&50 fexzk- ds cjkcj

cksry ,e-di vkSj

dkVZu lfgr

izR;sd fefy esa

DyksjksDohu

DyksjksDohu QksLQsV&64.5 fexzk-

30 fefy dh ok;y

18.58

20.16

bUtSD'ku

DyksjksDohu&40 fexzk- ds cjkcj

fQfYi vkWQ lhy vkSj

dkVZu lfgr

DyksjksDohu

DyksjksDohu QksLQsV&64.5 fexzk-

10x2 fefy dk

38.80

42.10

bUtSD'ku

DyksjksDohu&40 fexzk- ds cjkcj

,Ecj ,Ei;wy

DyksjksDohu

DyksjksDohu QksLQsV&64.5 fexzk-

5x5 fefy dk

30.48

33.07"

bUtSD'ku

DyksjksDohu&40 fexzk- ds cjkcj

,Ecj ,Ei;wy

*ljdkjh mn~xzg.kksa@djksa ds okLrfod Hkqxrku dh 'krZ ij ykxw gSaA

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

uksV %

¼d½

tgka dgha Hkh czkseksC;wVkby jcj LVksij ¼ysVsDl Ýh½ ds fy, ykxw ekudksa ds ekunaM ds vk/kkj vfrfjDr ykxr tksM+saA

¼[k½

;s dhersa fofufnZ"V iSd o leku izcyrk ds iSdksa ij mRikn 'kqYd vkSj LFkkuh; dj dks lfEefyr dj LraHk ¼6½ eas vf/kdre

[kqnjk dher ds :i esa fu;r dh tkrh gSa] vkSj dEiuh fdlh NwV dk nkok ugha dj ldrh] tc rd mls NwV ds fy;s

ljdkj@jk-vkS-ew-fu-izk- ls vkns'k izkIr u gksaA

¼x½

dEifu;k¡@fofuekZrk dsoy rHkh dj tksM+ ldrs gSa ;fn mUgksaus LraHk (5) esa mfYyf[kr ewY; ij ljdkj dks okLro esa Hkqxrku

fd;k gSA ;fn vf/kdre [kqnjk ewY; ¼lHkh djksa lfgr½ esa dksbZ fofHkUurk gks rks og ,uihih, dks Mhihlhvks] 1995 ds QkWeZ&V

esa lwfpr fd;k tkuk pkfg,A

¼?k½

og iSd ftldh dEiksft'ku leku gS ysfdu vkdkj esa vUrj gS] og izks&jkVk izkbftax vkns'k dk- vk- 83¼v½ fnukad 27.1.1998

ds rgr xksfy;ka vkSj dSilwy ds iRrk@fCyLVj ds fy, vk;sxhA

¼M-½

mi;ksx dh xbZ fHkUu iSfdax lkexzh ;k fHkUu vkS"k/k forj.k iz.kkyh ;k nkok fd, x, fdlh vU; fo'ks"k :i ds fy,] tc rd

dEifu;k¡ buds QkWewZys'kuksa ds fy, fo'ks"khÑr ewY; vuqeksnuksa gsrq ,uihih, ds ikl ugha tkrh] mPpre ewY; tSls mDr

dkWye la- 5 esa fo'ks"khÑr gS] ykxw gksaxsA

¼p½

vkS"k/k ewY; fu;a=k.k vkns'k] 1995 ds rgr fu;r dh xbZ mDr dhersa lHkh [email protected] }kjk vko';d :i ls

ykxw djuh gksxh ftl rjg ls bu fofufeZfr iSd ij vkS"k/k ,oa izlk/ku vf/kfu;e] 1940 dh 'krs± ykxw gksrh gaSA

¼N½

mDr dfFkr fofufeZfr dh [email protected] dEiuh ds fy, vfuok;Z gS fd og mDr dfFkr fofufeZfr ds la?kVu esa fdlh

Hkh cnyko ds fy, ,uihih, dks fyf[kr iwoZ lwpuk ds lkFk l{ke izkf/kdkjh ls vko';d iwoZ vuqeksnu izkIr djsaA

¼t½

mDr ds vk/kkj ij fudkyh xbZ vf/kdre dher] mRikn 'kqYd vkSj osV dh orZeku njksa ds vuqlkj 1.0850 ds ?kVd }kjk

vf/kdre dher ls xq.kk djds vf/kdre [kqnjk dher ls vf/kd ugha gksxhA

¼>½

mDr ds vuqlkj fudkyh xbZ vf/kdre [kqnjk dher] ;Fkk ykxw ljdkjh ysoh@djksa ds Hkqxrku dh 'krZ ds v/khu gS vkSj 1.0850

ds ?kVd esa t:jh lek;kstu] [email protected] dEiuh }kjk fd;k tkuk vko';d :i ls t:jh gS] tc dHkh mRikn 'kqYd

vkSj ;k osV dh orZeku nj esa cnyko gksrk gS] bl 'krZ ds v/khu fd bl izdkj ls x.kuk fd, x, mRikn 'kqYd vkSj ;k

osV] 1.0850 ds ?kVd ds vuqlkj [email protected] dEiuh ;k tSlh Hkh fLFkfr gks ds }kjk fdlh Hkh ekeys esa Hkqxrku fd,

x, okLrfod mRikn 'kqYd vkSj ;k osV ls vf/kd u gksA [email protected] dEiuh fo'ks"k :i ls bl 'krZ dk vuqikyu

lqfuf'pr djus ds fy, nk;h gksaxsA

¼V½

mDr lkj.kh esa O;kIr ugha gksus okys QkWewZys'ku@izcyrk¼dEiksft'ku½ ftlesa LrEHk 3 ds fdlh Hkh vuqlwfpr vkS"k/k ds rRo

ekStwn gks] rks ;g lkj.kh ds lEcfU/kr Øe la[;k ds mPpre ewY; ds 'krZ ds v/khu gksxk tSlk ekeyk gks] tc rd fd fuekZrk

us blds i'pkr~ ml QkWewZys'ku ds fy, ,uihih, }kjk fu/kkZfjr fo'ks"khÑr ewY; izkIr ugha fd;k gksA

¼B½

fofuekZrk ;k foi.ku dEiuh] mDr dfFkr vf/klwpuk dh rkjh[k ls 15 fnuksa ds Hkhrj blesa n'kkZ;s mPpre ewY;ksa vkSj 'krks±

dk ikyu ugha djrh gSa rks] os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 1995 ds izko/kkuksa ds v/khu C;kt

lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼M½

bl vkns'k esa fofufeZr iSdksa dh vf/kdre dher fu;r gksus ds ifj.kke Lo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq,

gSa] Lor% gh fujLr gks tk;saxsA

[dka- la-@142@10@2013@fo@Qk- la- 8¼10½@2013@Mhih@,uihih,-&fMoh--II]

euh"k xksLokeh] mi funs'kd

ORDER

New Delhi, the 20th December, 2013

S.O. 3790(E).—In order to implement the directions given in review order no. 31015/19/2013-PI.I dated 27.11.2013

passed by the Department of Pharmaceuticals for M/s. IPCA Ltd. against S.O. No. 1498(E) dated 07.06.2013 in respect of

Chloroquine Phosphate based formulations under DPCO 1995 and in exercise of the powers, conferred by sub-paragraphs

(1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997

issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the

Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O.

1498(E), dated 7th June, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of

¹Hkkx IIµ[k.M 3(ii)º

Hkkjr dk jkti=k % vlk/kj.k

things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes

the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in

column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the

Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size

specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl.

Name of the formulation

Strength

Pack

Ceiling

Equivalent

No.

Size

Price

MRP*(inclusive

(Rs.)

of all taxes)

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Each film coated tablet contains

“1.

Chloroquine Tablets

Chloroquine Phosphate-250mg

10’s

7.14

7.75

Strip/Blister

Chloroquine Tablets

Chloroquine Phosphate-500mg

5’s

6.94

7.53

Strip/Blister

Each 5ml contains

Chloroquine

Chloroquine Phosphate eq. to

60 ml Bottle

16.64

18.05

Suspension

Chloroquine - 50 mg

with M. Cup

& Carton

Each ml contains

Chloroquine

Chloroquine Phosphate -64.5mg

30 ml Vial

18.58

20.16

Injection

eq. to Chloroquine - 40 mg

with Flip-Off

Seal & Carton

Chloroquine

Chloroquine Phosphate -64.5 mg

10x2ml

38.80

42.10

Injection

eq. to Chloroquine - 40 mg

Amber Ampoule

Chloroquine

Chloroquine Phosphate -64.5 mg

5x5ml

30.48

33.07"

Injection

eq. to Chloroquine - 40 mg

Amber Ampoule

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)

Additional cost may be applicable as per norms towards use of bromobutyle rubber stopper (latex free) shall be

added wherever provided.

(b)

The prices fixed are the maximum retail prices in column (6) (inclcusive of excise duty and local taxes if any) for the

specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom,

unless specifically permitted by the Government/NPPA through an order.

(c)

The companies/manufacturers may added taxes only if they have paid actually to the Government on the price

mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated

to the NPPA in the Form-V of DPCO, 1995.

(d)

Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated

27.1.1998 for tablet and capsule packed in strip/blister.

(e)

For different packing material used or, different drug delivery systems or any other special features/forms claimed,

the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA

for specific price approvals for its formulations.

(f)

The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by

the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation

pack under the Drugs and Cosmetics Act, 1940.

(g)

The manufacturer and marketing company for the above said formulation shall be required to take the requisite

prior approval from the competent Authority for any change in the composition of the above said formulation with

written prior intimation to the National Pharmaceutical Pricing Authority.

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

(h)

The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor

of 1.0850 as per the existing rates of excise duty and VAT.

(i)

The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable and necessary

adjustment in the factor of 1.0850 shall necessarily be required to be made by the manufacturer/marketing company,

whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise

duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/

marketing company or as applicable as per the factor of 1.0850. The manufacturer/marketing company shall be

specifically liable to ensure the compliance of this condition.

(i)

Any other formulation / composition not covered in the above table that has any one of the scheduled drugs in

Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the

table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that

formulation.

(k)

The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes

hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount

along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

(l)

Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued

prior to this date of notification stand automatically withdrawn.

[PN/142/10/2013/F/F. No. 8(10)/2013/D.P./NPPA-Div.-II]

MANISH GOSWAMI, Dy. Director

Printed by the Manager, Government of India Press, Ring Road, Mayapuri, New Delhi-110064

and Published by the Controller of Publications, Delhi-110054.